Unaudited NAV for April

Arix Bioscience PLC (ARIX) Unaudited NAV for April 11-May-2022 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. PRESS RELEASE Arix Bioscience plc Unaudited NAV for April LONDON, 11 May 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company for date ended 30 April 2022 as follows: Date NAV Breakdown Total NAV NAV per share Listed Portfolio Unlisted Portfolio Cash Other Interests 30-Apr-22 (unaudited) £36.3m £57.7m £132.6m £2.8m £229.4m £1.78 [ENDS] Enquiries For more information on Arix, please contact: Arix Bioscience plc [phone] [e-mail] Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson [phone] [e-mail] About Arix Bioscience plc Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

ISIN:	GB00BD045071
Category Code:	NAV
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	160805
EQS News ID:	1348823

End of Announcement	EQS News Service